Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem-Pralubactam pharmacokinetics in healthy Chinese adults
NCT07124468Phase 1Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pralubactam in Infection, sponsored by Qilu Pharmaceutical. Primary endpoints: Plasma Concentration of Meropenem and Pralubactam at 5 days, Epithelial Lining Fluid Concentration of Meropenem and Pralubactam at 5 days and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
pralubactam
03
Conditions
Infection
Beyond the preview
Go deeper on NCT07124468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07124468.